United Therapeutics (NASDAQ:UTHR) Rating Reiterated by HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of United Therapeutics (NASDAQ:UTHR) in a report released on Thursday, Benzinga reports. The brokerage currently has a $300.00 price target on the biotechnology company’s stock.

Other equities research analysts have also issued research reports about the stock. Wedbush reiterated an outperform rating and set a $308.00 price objective on shares of United Therapeutics in a report on Thursday, February 22nd. Wells Fargo & Company lifted their price target on shares of United Therapeutics from $309.00 to $325.00 and gave the company an overweight rating in a research note on Thursday, March 7th. The Goldman Sachs Group raised United Therapeutics from a sell rating to a neutral rating and increased their price objective for the stock from $213.00 to $215.00 in a research note on Monday, February 12th. Leerink Partnrs reaffirmed an outperform rating on shares of United Therapeutics in a research report on Monday, February 5th. Finally, SVB Leerink initiated coverage on United Therapeutics in a report on Monday, February 5th. They issued an outperform rating and a $330.00 price objective for the company. One research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and a consensus price target of $308.78.

United Therapeutics Trading Up 1.7 %

Shares of UTHR traded up $4.27 during mid-day trading on Thursday, reaching $262.40. 779,523 shares of the company’s stock traded hands, compared to its average volume of 541,180. United Therapeutics has a 12 month low of $204.44 and a 12 month high of $262.51. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.77 and a quick ratio of 4.28. The stock has a market cap of $11.64 billion, a P/E ratio of 12.41 and a beta of 0.54. The stock’s 50-day moving average is $236.86 and its two-hundred day moving average is $229.40.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $6.17 EPS for the quarter, beating the consensus estimate of $5.63 by $0.54. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The company had revenue of $677.70 million for the quarter, compared to the consensus estimate of $620.31 million. During the same quarter in the prior year, the company posted $4.86 EPS. United Therapeutics’s quarterly revenue was up 33.7% on a year-over-year basis. Research analysts forecast that United Therapeutics will post 23.75 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Paul A. Mahon sold 6,000 shares of the firm’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $215.31, for a total value of $1,291,860.00. Following the sale, the executive vice president now directly owns 36,599 shares in the company, valued at approximately $7,880,130.69. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $258.09, for a total transaction of $929,124.00. Following the transaction, the chief executive officer now directly owns 130 shares in the company, valued at approximately $33,551.70. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Paul A. Mahon sold 6,000 shares of the company’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $215.31, for a total value of $1,291,860.00. Following the transaction, the executive vice president now directly owns 36,599 shares in the company, valued at $7,880,130.69. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 141,790 shares of company stock worth $33,572,685. 12.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On United Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. DekaBank Deutsche Girozentrale boosted its stake in United Therapeutics by 54.4% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 94,643 shares of the biotechnology company’s stock worth $20,617,000 after purchasing an additional 33,338 shares in the last quarter. Nordea Investment Management AB grew its holdings in shares of United Therapeutics by 155.2% during the fourth quarter. Nordea Investment Management AB now owns 38,698 shares of the biotechnology company’s stock valued at $8,427,000 after buying an additional 23,532 shares during the last quarter. Duality Advisers LP increased its position in shares of United Therapeutics by 56.1% in the 4th quarter. Duality Advisers LP now owns 15,642 shares of the biotechnology company’s stock valued at $3,440,000 after acquiring an additional 5,622 shares during the period. Louisiana State Employees Retirement System acquired a new position in shares of United Therapeutics in the fourth quarter valued at about $2,903,000. Finally, O Shaughnessy Asset Management LLC raised its stake in shares of United Therapeutics by 4.9% in the third quarter. O Shaughnessy Asset Management LLC now owns 2,300 shares of the biotechnology company’s stock worth $520,000 after purchasing an additional 107 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.